Results 91 to 100 of about 4,245 (206)

Clinical Implications of Ki‐67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions

Journal of Hepato-Biliary-Pancreatic Sciences, Volume 33, Issue 2, Page 141-150, February 2026.
In this retrospective study of metastatic and recurrent pancreatic neuroendocrine tumors, Murakami and colleagues demonstrated frequent discordance in Ki‐67 index and World Health Organization grade between primary and secondary lesions. Increased proliferation did not compromise survival, likely reflecting treatment adaptation. Rare hormonal phenotype
Masatoshi Murakami, Nao Fujimori, Kazuhide Matsumoto, Keijiro Ueda, Kohei Nakata, Masafumi Nakamura, Takeo Yamamoto, Yoshinao Oda, Tetsuhide Ito, Yoshihiro Ogawa   +9 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumours: A Scientometric Analysis

The purpose of this scientometric analysis is to explore the global research landscape for Peptide Receptor Radionuclide Therapy (PRRT) using 7608 records gathered between 2000 and 2025. The study demonstrates a steady rise in publication output, with a notable increase in the recent decade, indicating greater clinical significance and scientific ...
Deepika N., Sarangapani, R
openaire   +3 more sources

Gold Nanoparticles Loaded With Lutetium‐177 Labeled DOTA‐TATE Exhibit Superior AR42J Cell Affinity and Extended Blood Circulation in AR42J Tumor Xenografts

Nano Select, Volume 7, Issue 2, February 2026.
The present study reports the development of a gold nanoparticle‐based delivery system functionalized with the established radiopharmaceutical [177Lu]Lu‐DOTA‐TATE. This design aims to enhance tumor‐targeting efficacy and improve the overall in vivo pharmacokinetic profile. In vitro studies demonstrated enhanced specificity toward somatostatin receptor (
Dheeraj Kumar, Rani Gnanasekar, Sheela Muralidharan, Shubhangi Mirapurkar, Krishna Mohan Repaka, Anupam Mathur, Madhava B. Mallia   +6 more
wiley   +1 more source

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Endocrine Oncology
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting ...
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug   +6 more
doaj   +1 more source

Advanced Peptide Receptor Radionuclide Therapy to Overcome Refractory Hypoglycemic Insulinoma: A Case Report and Review of the Literature

Journal of Medical Sciences
We reported the case of a 42-year-old man with refractory hypoglycemia caused by an inoperable malignant insulinoma and multiple liver metastases. The patient initially received bi-weekly intramuscular injections of octreotide long-acting release and a ...
Yi-Hsiang Huang, Sheng-Chiang Su, Tzu-Chuan Huang   +2 more
doaj   +1 more source

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Surgical Case Reports
Background Peptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive unresectable liver metastases of pancreatic neuroendocrine tumors (PNETs).
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada   +8 more
doaj   +1 more source

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source

Peptide-receptor radionuclide therapy for endocrine tumors

, 2009
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors.
Martijn van Essen, Essen, Martijn, Roelf Valkema, Eric P. Krenning, Dik J. Kwekkeboom, Krenning, Eric, Valkema, R., Jong, Marion, Kwekkeboom, Dik, Boen L. R. Kam, Kam, BLR, Marion de Jong   +11 more
core   +1 more source

Peptide receptor radionuclide therapy for metastatic paragangliomas

, 2016
There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on ...
Ramaswami R., Black J. R. M., Adjogatse D., Pinato D. J., Sharma R., Tan T. M.   +5 more
core   +2 more sources